The overall prognosis of pancreatic cancer is poor, the 5-year survival rate being as low as 0.2-3.4% (Gudjonsson, 1987) . Even after surgery for cure the 5-year survival in a metaanalysis was only 3.4% (Gudjonsson, 1987) , although in a few recent studies higher survival rates have been reported (Trede et al., 1990; Cameron et al., 1991) . The It has been suggested that tumour markers might be used for evaluating prognosis in pancreatic cancer, but only a few studies have been reported. A positive correlation between low initial levels of CEA and CA 19-9 and survival has been described Bottger et al., 1990) . However, in these studies stage of the disease was not taken into account.
The aim of this study was to evaluate the prognostic value of the preoperative serum levels of CA 19-9 and CEA in different stages of pancreatic cancer and to develop a method of determining the optimal cut-off level for prognostic evaluation. (Koprowski et al., 1979) , and carcinoembryonic antigen (CEA), first detected in 1965 (Gold & Freedman, 1965) Kaplan and Meier (1958) . Patients were divided in groups having a preoperative tumour marker value above or below a certain cut-off level and their survival was compared. The statistical significance of the difference in survival of the groups was calculated using the log-rank test (Peto et al., 1977) When analysing all patients, there was a significant difference in survival between those with a preoperative CA 19-9 level below (69 patients) 370 U ml1 and those whose level was above (82 patients) 370 U ml' (P<0.01) ( Table I) . In stage I patients, the median survival was 18.5 months for patients having a CA 19-9 value lower than 370 U ml1 (16/23 patients), and 17.5 months for those with a higher value (7/23 patients). The corresponding mean values were 25.6 months and 22.8 months respectively. The difference between the survival curves was not statistically significant (P>0.05) (Figure 3 ; Table I ). Nor was there any significant difference when analysing all patients with resectable disease (stage I plus stage IH-III resectable).
Patients and methods

Patients
In stage II-III patients, the median survival for 24 patients with a level lower than 370 U ml-' was 13 months, compared with 6.4 months for 25 patients with a serum concentration greater than 370 U ml-'. The difference between the survival curves was statistically significant (P<0.05) ( Table I) .
When excluding stage 11-Ill patients in whom the tumour was resected, and analysing only patients with non-resectable disease, the difference between survival curves of patients with a CA 19-9 level lower vs higher than 370 U ml' was more significant (P<0.01). The median survival for 21 patients with CA 19-9 below 370 U ml' was 11.9 months compared with 5.2 months for 21 patients with a serum concentration greater than 370 U ml-'. The corresponding mean values were 13.2 months and 6.5 months respectively ( Figure 4 ; Table I ).
In stage IV patients the median survival was 2.7 months for patients having a value lower than 370 U ml' (29/79 patients) and 2 months for those with a higher value (50/79 patients). The corresponding mean values were 4.8 and 3.8 months respectively. The difference between the survival curves was not statistically significant ( Figure 5 ; Table I ).
CEA
When analysing all patients, there was a significant difference in survival between those with a preoperative CEA level below (104 patients) vs above (34 patients) 15 ng ml' (P <0.001).
Only one stage I patient out of 18 had a preoperative CEA value above 15 ng ml-', and this did not allow statistically meaningful analysis. The same was true when analysing all patients with resectable disease.
Six out of 47 stage II-III patients had a preoperative CEA value above 15 ng ml-'. All six patients belonged to the group of patients with non-resectable disease. The difference in survival between patients with CEA below vs above this value was not significant.
Of stage IV patients, 27 out of 73 had a CEA value higher than 15 ng ml-' and a median survival of 1 month compared with 3 months for those with a lower value. The corresponding mean values were 2 and 5 months. The difference was statistically significant (P<0.01). Combination of CA 19-9 and CEA When patients with preoperative CA 19-9 higher than 370 U mlhl and CEA higher than 15 ng ml-' were compared with patients who had marker values below these cut-off levels, the differences in the survival curves were not significant in any subgroup analysed. Nor were there significant differences in any group when comparing patients who had either CA 19-9 higher than 370 U ml' or CEA higher than 15 ng ml' with those who had lower marker levels.
Discussion
In pancreatic cancer very few factors that influence prognosis are known. Stage of disease is known to correlate with survival, and this was also verified in our study. New prognostic markers would be of great value, and interest has recently been focused on immunological tumour markers. In this study, the prognostic value of CA 19-9 and CEA, two markers commonly used as diagnostic tests for pancreatic cancer, was evaluated.
Carcinoembryonic antigen (CEA), detected in 1965 by Gold and Freedman, was for more than a decade the only tumour marker of any clinical value in the diagnosis of pancreatic cancer. During the last 10 years it has been replaced by CA 19-9, which has a clearly higher sensitivity of 72-79% (Klapdor et al., 1984; Haglund et al., 1986; Steinberg et al., 1986; Benini et al., 1988) . CA 19-9 is also sensitive in detecting recurrences of pancreatic cancer after operation for cure (Klapdor et al., 1984; Haglund et al., 1986 Haglund et al., , 1989 . Both markers are also used as diagnostic tests for other forms of gastrointestinal cancer.
It has been suggested that preoperative levels of tumour markers could be used for evaluating prognosis, but very few studies have been published. For both CEA and CA 19-9 a positive correlation between a low marker level and survival has been shown Bottger et al., 1990) . In neither study were the survival rates correlated with clinical stage, which is known to clearly correlate with prognosis. In this study, we evaluated whether high or low preoperative CA 19-9 and CEA levels might predict prognosis in patients of the same stage of pancreatic cancer.
We found it appropriate to exclude patients in stages I-III who died within 30 days of operation. Also, some other factors might alter the results, which is why different subanalyses were performed, as discussed below.
The CA 19-9 antigen corresponds to sialylated Lewisa blood group substance . Therefore, it has been suggested that individuals lacking the Lewis gene (Lewisa-b-), i.e. about 5-10% in different populations, are not able to produce the CA 19-9 antigen . Thus, the survival data of these patients might distort the overall results. On the other hand, Masson et al. (1990) found no difference in CA 19-9 expression between patients of different Lewis blood groups. Patients with a CA 19-9 level below the detection limit of the test (<6.2 U ml-') might represent 'non-producers' of the antigen, although we did not determine the Lewis status of our patients. Excluding patients with CA 19-9 below 6.2 U ml-' from analysis did not alter the results of our study.
Elevated values of CA 19-9 and CEA are frequently seen in benign extrahepatic biliary obstruction, and it has been suggested that in patients with pancreatic cancer obstruction of the common bile duct might contribute to the elevation of serum marker levels Carr-Locke, 1980; Haglund et al., 1986 Haglund et al., , 1989 Barone et al., 1988; . If the patients of this study had been further divided into patients with or without jaundice, the groups would have been too small for meaningful statistical analysis. However, no clear difference in survival was seen, when comparing patients presenting with jaundice (serum bilirubin >201imol 1) with those without jaundice.
For diagnostic purposes, the upper limits of normal, i.e. the recommended cut-off levels of different markers, were determined from sera of healthy individuals. This level was 37 U ml-' for the CA 19-9 assay used in this study and 3 ng ml-' for the CEA assay. When using these cut-off levels for prognostic evaluation, no significant differences in survival were seen within the different stage groups or between patients with a higher vs lower preoperative marker value.
Since no established cut-off value for prognostic evaluation was available, we developed a computer program to determine the lowest cut-off value that divided the patients in two groups with a significant difference in survival. In stage II-III patients the optimal cut-off value was almost exactly 370 U ml-', which is tenfold greater than the cut-off level used for diagnostic purposes. Since no differences in survival between patient groups were found at any cut-off level in stages I and IV, the cut-off level of 370 U ml-' was chosen for further analysis.
Our study confirmed that there is a clear and significant difference in survival between patients with pancreatic cancer with a low vs high preoperative tumour marker level, if stage of disease is not taken into account. However, when patients were divided according to stage, the differences were significant only in stage 11-III, both including and excluding patients with resectable disease, and only for CA 19-9. The difference in survival may reflect a difference in biological behaviour between tumours associated with a low level in contrast to a high level of CA 19-9. On the other hand, the stage II-111 group is rather non-homogeneous, including patients with local disease, but with varying degree of spread to local lymph nodes. The size of the primary tumour may also vary markedly. Therefore, the difference in survival between patients with low and high CA 19-9 values might also reflect differences in tumour burden and spread of disease.
In stage I patients, the prognosis seemed to be independent of the preoperative serum expression of CA 19-9 and CEA, which was also true when analysing all patients with resectable disease. This may be explained by the fact that all patients underwent operation for cure, in which all macroscopic tumour tissue was removed. Therefore, postoperatively they may, from a prognostic point of view, be considered to be at the same starting point.
In stage IV patients, no difference in survival was seen between patients with a high or low CA 19-9 level, independently of the cut-off level chosen. This is probably explained by the very short overall survival of these patients. When stage IV patients were divided in two groups according to the preoperative CEA value, a difference was found in survival. However, this was true only for patients with extremely high preoperative values, above 15 ng ml1'. In clinical practice, this finding is of limited value because of the very short survival in both groups, 5 months for patients with a value lower than 15 ng ml-' and 2 months for those with a higher value.
In conclusion, when evaluating prognosis, the preoperative serum level of CA 19-9 seems to be of some clinical value in stage II-III patients, in whom spread of disease may be difficult to assess even at surgery.
One explanation for the limited prognostic value of preoperative CA 19-9 and CEA levels might be the fact that the serum level of a tumour marker is not a reflection of the ability of the tumour tissue to synthesise the antigen, but rather a consequence of many other factors affecting the amount of circulating antigen. Among these factors are secretion of produced antigen into the bloodstream, metabolism and excretion of the antigen and occurrence of liver metastases. These factors are difficult to measure and the mechanisms are partly unknown. Immunohistochemistry seems a more reliable method of evaluating synthesis of the antigen, and the correlation between CA 19-9 staining and prognosis should be studied.
